Cochlear spiral ganglion neuron degeneration following cyclodextrin-induced hearing loss
HPβCD as a treatment for Niemann-Pick Type C1 disease can reduce some debilitating symptoms and extend life span, but the
Category: CD as API
The use of β-CDs to improve honey bee health
Honey bees are essential members of the natural ecosystems and the modern agriculture, yet their colonies are collapsing worldwide. In
Gd(3+) Complexes Conjugated to Cyclodextrins
In the search for improvement in the properties of gadolinium-based contrast agents, cyclodextrins (CDs) are interesting hydrophilic scaffolds with high
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and
Press Release – Development of Autophagy Inducing Cyclodextrin Derivatives for Aging-associated Diseases
CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.
Cyclodextrin-mediated quorum quenching
Bacterial Quorum Sensing is a cell-to-cell communication process, in which, bacteria, performing cooperative behaviour, produce and detect extracellular signalling chemicals, to monitor
Targetrin Therapeutics, a Cyclolab és EpiPharma új közös vállalata ciklodextrin-peptid konjugátumok fejlesztésére és értékesítésére
A Cyclolab, a ciklodextrin-kutatás, -fejlesztés és -gyártás nagy múltú, világszerte ismert központja valamint az EpiPharma, bio-gyógyszerészeti szolgáltató és peptidegyógyszereket fejlesztő
Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and Commercialize novel conjugated Cyclodextrin – Peptide drugs
Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development
Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo
Special Issue “Pharmaceutical and Biomedical Applications of Cyclodextrins and Derivatives”
This Special Issue in Pharmaceutics will collect the latest innovative researches in the field of pharmaceutical and biomedical applications of